Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study

References

• MontgomeryWLiuLStenslandMDXueHBTreuerTAscher-SvanumHThe personal, societal, and economic burden of schizophrenia in the People’s Republic of China: implications for antipsychotic therapyClinicoecon Outcomes Res2013540741823983478
   PubMedGoogle Scholar
• CahoonEKMcGintyEEFordDEDaumitGLSchizophrenia and potentially preventable hospitalizations in the United States: a retrospective cross-sectional studyBMC Psychiatry2013251337
   Google Scholar
• LinHCHuangCCChenSFChenYHIncreased risk of avoidable hospitalization among patients with schizophreniaCan J Psychiatry201156317117821443824
   PubMed Web of Science ®Google Scholar
• LehmanAFLiebermanJADixonLBPractice guideline for the treatment of patients with schizophrenia, second editionAm J Psychiatry20041612 Suppl15615000267
   PubMed Web of Science ®Google Scholar
• CaseyDELong-term treatment goals: enhancing healthy outcomesCNS Spectr2003811 Suppl 2262814978456
   PubMed Web of Science ®Google Scholar
• AwadAGVorugantiLNThe burden of schizophrenia on caregivers: a reviewPharmacoeconomics200826214916218198934
   PubMed Web of Science ®Google Scholar
• PandinaGJLindenmayerJPLullJA randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophreniaJ Clin Psychopharmacol201030323524420473057
   PubMed Web of Science ®Google Scholar
• BrownMTBussellJKMedication adherence: WHO cares?Mayo Clin Proc201186430431421389250
   PubMed Web of Science ®Google Scholar
• HoPMBrysonCLRumsfeldJSMedication adherence: its importance in cardiovascular outcomesCirculation2009119233028303519528344
   PubMed Web of Science ®Google Scholar
• LawMRSoumeraiSBRoss-DegnanDAdamsASA longitudinal study of medication nonadherence and hospitalization risk in schizophreniaJ Clin Psychiatry2008691475318312037
   PubMed Web of Science ®Google Scholar
• WeidenPJKozmaCGroggALocklearJPartial compliance and risk of rehospitalization among California Medicaid patients with schizophreniaPsychiatr Serv200455888689115292538
   PubMed Web of Science ®Google Scholar
• AlphsLBossieCASliwaJKMaYWTurnerNOnset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trialAnn Gen Psychiatry20111011221481243
   PubMed Web of Science ®Google Scholar
• LafeuilleMHLaliberte-AugerFLefebvrePFroisCFastenauJDuhMSImpact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysisBMC Psychiatry20131322124016390
   PubMed Web of Science ®Google Scholar
• LambertTOlivaresJMPeuskensJEffectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and BelgiumAnn Gen Psychiatry2011101021463526
   PubMed Web of Science ®Google Scholar
• VelliganDIWeidenPJSajatovicMThe expert consensus guideline series: adherence problems in patients with serious and persistent mental illnessJ Clin Psychiatry200970Suppl 4146 quiz 47–4819686636
   PubMed Web of Science ®Google Scholar
• Invega® Sustenna® (paliperidone palmitate extended-release injectable suspension) [package insert]Titusville, NJJanssen Pharmaceuticals, Inc2014
   Google Scholar
• CitromeLPaliperidone palmitate – review of the efficacy, safety and cost of a new second-generation depot antipsychotic medicationInt J Clin Pract201064221623919886879
   PubMed Web of Science ®Google Scholar
• HoySMScottLJKeatingGMIntramuscular paliperidone palmitateCNS Drugs201024322724420155997
   PubMed Web of Science ®Google Scholar
• KramerMSimpsonGMaciulisVPaliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled studyJ Clin Psychopharmacol200727161417224706
   PubMed Web of Science ®Google Scholar
• PotkinSGGharabawiGMGreenspanAJA double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalizationSchizophrenia Res2006851254265
   Web of Science ®Google Scholar
• SamtaniMNGopalSGassmann-MayerCAlphsLPalumboJMDosing and switching strategies for paliperidone palmitateCNS Drugs2011251082984521936586
   PubMed Web of Science ®Google Scholar
• OwenRPaliperidone palmitate injection: its efficacy, safety and tolerability in schizophreniaDrugs Today (Barc)201046746347120683501
   PubMed Web of Science ®Google Scholar
• PandinaGLaneRGopalSA double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophreniaProg Neuropsychopharmacol Biol Psychiatry201135121822621092748
   PubMed Web of Science ®Google Scholar
• ZhangFSiTChiouCFEfficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophreniaNeuropsychiatr Dis Treat20151111225565846
   PubMed Web of Science ®Google Scholar
• Bugarski-KirolaDWangAAbi-SaabDBlattlerTA phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia – results from the CandleLyte studyEur Neuropsychopharmacol20142471024103624735806
   PubMed Web of Science ®Google Scholar
• De la GandaraJSan MolinaLRubioGRodriguez-MoralesAHidalgo BorrajoRBuronJAExperience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE StudyExpert Rev Neurother20099101463147419831836
   PubMed Web of Science ®Google Scholar
• MeltzerHYCucchiaroJSilvaRLurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled studyAm J Psychiatry2011168995796721676992
   PubMed Web of Science ®Google Scholar
• MarderSRDavisJMChouinardGThe effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trialsJ Clin Psychiatry199758125385469448657
   PubMed Web of Science ®Google Scholar
• National Institute of Mental HealthClinical Global Impressions (CGI)GuyWECDEU Assessment Manual for PsychopharmacologyBethesdaUS Department of Health, Education and Welfare1976218222
   Google Scholar
• MorosiniPLMaglianoLBrambillaLUgoliniSPioliRDevelopment, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioningActa Psychiatr Scand2000101432332910782554
   PubMed Web of Science ®Google Scholar
• HogartyGEUlrichRThe discharge readiness inventoryArch Gen Psychiatry19722654194265063078
   PubMed Web of Science ®Google Scholar
• PotkinSGGharabawiGMGreenspanAJPsychometric evaluation of the Readiness for Discharge QuestionnaireSchizophr Res200580220321216102943
   PubMed Web of Science ®Google Scholar
• GopalSHoughDWXuHEfficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response studyInt Clin Psychopharmacol201025524725620389255
   PubMed Web of Science ®Google Scholar
• KramerMLitmanRHoughDPaliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety studyInt J Neuropsychopharmacol201013563564719941696
   PubMed Web of Science ®Google Scholar
• NasrallahHAGopalSGassmann-MayerCA controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophreniaNeuropsychopharmacology201035102072208220555312
   PubMed Web of Science ®Google Scholar
• LiHRuiQNingXXuHGuNA comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophreniaProg Neuropsychopharmacol Biol Psychiatry20113541002100821315787
   PubMed Web of Science ®Google Scholar
• FuDJBossieCAKern SliwaJMaYWAlphsLPaliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimensClin Schizophr Relat Psychoses201482101109109A23446197
   PubMedGoogle Scholar
• BossieCASliwaJKMaYWFuDJAlphsLOnset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trialBMC Psychiatry2011117921569242
   PubMed Web of Science ®Google Scholar
• AlphsLBossieCAFuDJMaYWKern SliwaJOnset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophreniaExpert Opin Pharmacother20141571029104224754314
   PubMed Web of Science ®Google Scholar
• LeuchtSKaneJMEtschelEKisslingWHamannJEngelRRLinking the PANSS, BPRS, and CGI: clinical implicationsNeuropsychopharmacology200631102318232516823384
   PubMed Web of Science ®Google Scholar
• LeuchtSKaneJMKisslingWHamannJEtschelEEngelRClinical implications of Brief Psychiatric Rating Scale scoresBr J Psychiatry200518736637116199797
   PubMed Web of Science ®Google Scholar
• LeuchtSKaneJMKisslingWHamannJEtschelEEngelRRWhat does the PANSS mean?Schizophr Res2005792–323123815982856
   PubMed Web of Science ®Google Scholar
• HoughDNuamahIFLimPSampsonAGagnonDDRothmanMIndependent effect of paliperidone extended release on social functioning beyond its effect on positive and negative symptoms of schizophrenia: a mediation analysisJ Clin Psychopharmacol200929549649719745652
   PubMed Web of Science ®Google Scholar
• HargarterLCherubinPBergmansPIntramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychoticsProg Neuropsychopharmacol Biol Psychiatry201458c1725448776
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use, European Medicines AgencyGuideline on Clinical Investigation of Medicinal Products, Including Depot Preparations in the Treatment of SchizophreniaLondonEuropean Medicines Agency2012 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/10/WC500133437.pdfAccessed November 24, 2014
   Google Scholar